ChiCTR2300068316: A multicenter, randomized, placebo-controlled clinical study to evaluate the safety and efficacy of HL231 inhalation solution in the treatment of chronic obstructive pulmonary disease (COPD) |
|
|
| Not yet recruiting | 2 | 18 | | B, F, D (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;D, B, F (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;F, D, B (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;D, F, B (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;F, B, D (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;B, D, F (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Haisco Pharmaceutical Group Co., Ltd. | Chronic obstructive pulmonary disease (COPD) | | | | |
ChiCTR2100053138: A trial to evaluate the pharmacokinetics and safety tolerability of a single inhalation of HL231 inhaled solution in healthy Chinese volunteers |
|
|
| Recruiting | 1 | 16 | | The ratio of male to female was 1:1, and the subjects received low dose HL231 inhalation solution (132μg/72μg), control drug, medium dose HL231 inhalation solution (261μg/141μg), and high dose HL231 inhalation solution (516μg/279μg) in 4 cycles in sequence ;The male to female ratio was 1:1, and the subjects were treated with HL231 inhalation solution (261μg/141μg), HL231 inhalation solution (132μg/72μg), HL231 inhalation solution (516μg/279μg) and control drug in 4 cycles in sequence ;The ratio of male to female was 1:1, and the subjects received HL231 inhalation solution of high dose (516μg/279μg), HL231 inhalation solution of medium dose (261μg/141μg), control drug, and low-dose HL231 inhalation solution of 132μg/72μg in 4 cycles in sequence ;The ratio of male to female was 1:1, and the subjects received control drug, high dose HL231 inhalation solution (516μg/279μg), control drug, low dose HL231 inhalation solution (132μg/72μg), medium dose HL231 inhalation solution (261μg/141μg) in 4 cycles in sequence | Research Center for Clinical Trials of the Third Xiangya Hospital of Central South University; Research Center for Clinical Trials of the Third Xiangya Hospital of Central South University, Haisco Pharmaceutical Group Co., Ltd | Chronic obstructive pulmonary disease (COPD) | | | | |